- Home
- TELO
as 12-17-2024 4:00pm EST
Stocks
Telomir Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells.
| Founded: | 2021 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 124.1M | IPO Year: | 2024 |
| Target Price: | N/A | AVG Volume (30 days): | 256.6K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.79 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.11 - $20.72 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest TELOMIR PHARMACEUTICALS INC News
TELO Breaking Stock News: Dive into TELO Ticker-Specific Updates for Smart Investing
ACCESSWIRE
6 days ago
Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price
ACCESSWIRE
15 days ago
Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Groundbreaking Preclinical Study With Telomir-1
Zacks Small Cap Research
15 days ago
TELO Test Results Continue to Excite
MT Newswires
a month ago
Sector Update: Health Care Stocks Advance Late Afternoon
MT Newswires
a month ago
Sector Update: Health Care Stocks Climb Thursday Afternoon
MT Newswires
a month ago
Sector Update: Health Care
MT Newswires
a month ago
Telomir Pharmaceuticals Says Telomir-1 Preclinical Data Show Age Reversal; Shares Rise
ACCESSWIRE
a month ago
Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Compare TELO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TELO TELOMIR PHARMACEUTICALS INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.